Validation of treatment induced specific adverse effect as a predictor of treatment benefit: A case study of NCIC CTG BR21

Contemporary Clinical Trials

Volumn 29, Issue 4, 2008, Pages 527-536

  Ding, K ^a   Pater, J ^a   Whitehead, M ^a   Seymour, L ^a   Shepherd, F A ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Cox regression model; Phase III clinical trials; Surrogate endpoints; Targeted therapies; Time dependent covariate

Indexed keywords

ERLOTINIB; LACTATE DEHYDROGENASE; PLACEBO;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ERUPTIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 44249105418     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2008.01.004     Document Type: Article

References (24)

1. Soulieres D., Senzer N.N., Vokes E.E., Hidalgo M., Agarwala S.S., and Siu L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 1 (2004) 77-85
2. Clark G.M., Pérez-Soler R., Siu L., Gordon A., and Santabárbara P. Rash severity is predictive of increased survival with erlotinib hydrochloride. Proc Am Soc Clin Oncol 22 (2003) 196 [Abstract 786]
3. M. Buyse, P. Thirion, R.W. Carlson, et al., Relation between tumour response to first line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet 356: 373-378.
4. Bruzzi P., Del Mastro L., Sormani M.P., et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 23 22 (2005) 5117-5125
5. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8 (1989) 431-440
6. Feedman L.S., Graubard B.L., and Schatzkin A. Statistical validation of intermediate endpoints for chronic disease. Stat Med 11 (1992) 167-178
7. Lin D.Y., Fischl M.A., and Schoenfeld D.A. Evaluating the role of CD4 lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Statist Med 12 (1993) 835-842
8. Buyse M., and Molenberghs G. Criteria for validation of surrogate endpoints in randomized experiments. Bimoetrics 54 (1998) 1014-1029
9. Alonso A., Molenberghs G., Geys H., Buyse M., and Vangeneugden. A unifying approach for surrogate marker validation based on Prentice's criteria. Stat Med 25 (20006) 205-221
10. Cox D.R. Regression models and life tables. J Royal Stat Soc Ser B 34 (1972) 187-220
11. Anderson J.R., Cain K.C., and Gelber R.D. Analysis of survival by tumor response. J Clin Oncol 1 11 (1983) 710-719
12. Burzykowski T., Molenberghs G., Buyse M., Geys H., and Renard D. Validation of surrogate endpoints in multiple randomized clinical trials with failure time endpoints. Appl Statist 50 (2001) 405-422
13. Burzykowski T., Molenberghs G., Buyse M., Geys H., and Renard D. Validation of surrogate endpoints by using data from randomized clinical trials: a case-study in advanced colorectal cancer. J R Statist Scc A 167 (2004) 103-124
14. Baker S.G. A simple meta-analysis approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint. Biostatistics 7 1 (2006) 58-70
15. Mantel N., and Byar D.P. Evaluation of response-time data involving transient state: an illustration using heart-transplant data. JASA 69 (1974) 81-86
16. Lin D.Y., Fleming T.R., and De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 16 (1997) 1515-1527
17. Lloyd D.F.i.s.h.e.r., and Lin D.Y. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 20 (1999) 145-157
18. Segaert S., and Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16 (2005) 1425-1433
19. Clark G.M., Pérez-Soler R., Siu L., Gordon A., and Santabárbara P. Rash severity is predictive of increased survival with erlotinib hydrochloride. Proc Am Soc Clin Oncol 22 (2003) 196 [Abstract 786]
20. Shepherd F., Pereira J.R., Ciuleanu T., Tan E.H., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 2 (2005) 123-132
21. Grambsch P.M., and Therneau T.M. Proportional hazard tests in diagnostics based on weighted residuals. Biometrica 81 (1994) 515-526
22. Clark G.M., Zborowski D.M., Santabarbara P., et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Clin Lung Cancer 7 (2006) 389-394
23. Buyse M., Molenberghs G., Burzykowski T., Renard D., and Geys H. The validation of surrogate endpoints in meta-analysis of randomized experiments. Biostatistics 1 1 (2000) 49-57
24. Molenberghs G., Buyse M., Geys H., Renard D., Burzykowski T., and Alonso A. Statistical challenges in the evaluation of surrogate endpoints in randomized clinical trials. Control Clin Trials 23 (2002) 607-625